One-Liner
A mobile tool helping families of children with ultra-rare conditions (age 4-11 APDS, pediatric UC) navigate multi-drug insurance prior-authorization appeals across different payers simultaneously.
AI Thinking Process
Scale Shift engine fired. Institutional → family scale. Payer prior-auth navigation for ultra-rare pediatric drug approvals (Joenja for APDS age 4-11, Stelara pediatric UC age 2+) currently runs at hospital level. G233 Scale Shift Suspension gene watching — doubled Pass 2 burden.
Buyer-incumbent gap: Pharming's own patient services program supports Joenja access. J&J's One Path supports Stelara. Fatal buyer-incumbent gap for family-side app — families already have a free white-glove concierge for each individual drug.
Multi-drug case where child has APDS + Stelara + Vertex trial simultaneously — pharma programs don't talk to each other. Real gap. But TAM: multi-drug ultra-rare pediatric families are 5,000-20,000 in the US. Frequency Trap and Adoption Barrier both fatal.
Specialty pharmacy pivot (Accredo, CVS Caremark specialty) as cross-payer, cross-drug prior-auth reasoning tool. Real segment with real budget. But 10+ prior-auth ideas in idea-history (HCP-side and patient-side) and duplicate risk high.
Fundamental failure: TAM too small for family-side product; pharma-brand navigators own single-drug segment; specialty-pharmacy pivot is a template hit. G183 recency check fired — small population + strong pastor + incumbent-free combination seems ripe but the math kills it.
Kill Reason
The addressable patient population — families of children with multi-drug ultra-rare diagnoses requiring simultaneous cross-payer appeal — is 5,000 to 20,000 US families maximum. For each individual drug, the pharmaceutical manufacturer already runs a free white-glove patient-navigator service (Pharming's own program for Joenja, J&J's One Path for Stelara). The only gap is multi-drug coordination, but the patient count in that exact category is too small to sustain a standalone product, and the specialty-pharmacy pivot is a template the engine has generated many times before.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.